Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) Gross Margin (2024 - 2025)

X4 Pharmaceuticals' Gross Margin history spans 2 years, with the latest figure at 85.83% for Q4 2025.

  • For Q4 2025, Gross Margin rose 689.0% year-over-year to 85.83%; the TTM value through Dec 2025 reached 83.6%, up 1477.0%, while the annual FY2025 figure was 83.6%, 1477.0% up from the prior year.
  • Gross Margin reached 85.83% in Q4 2025 per XFOR's latest filing, up from 80.11% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 85.83% in Q4 2025 to a low of 52.4% in Q2 2024.